
Head of R&D at ALK Henrik Jacobi thinks the decision to move into peanut allergies makes sense, as the firm already has a lot of experience of developing tablet-based vaccines.
On Monday, the firm revealed that it was starting a phase I study within the indication.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app